Literature DB >> 15064773

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium.

Susan P Fosmire1, Erin B Dickerson, Allyson M Scott, Stacie R Bianco, Marilyn J Pettengill, Heather Meylemans, Marcia Padilla, Ashley A Frazer-Abel, Nasim Akhtar, David M Getzy, John Wojcieszyn, Matthew Breen, Stuart C Helfand, Jaime F Modiano.   

Abstract

Hemangiosarcoma (HSA) is a common untreatable cancer of dogs that resembles human angiosarcoma. Detailed studies of these diseases have been historically hindered by the paucity of suitable reagents. Here, we show that expression of CD117 (c-Kit) can distinguish primitive (malignant) from mature (benign) proliferative endothelial lesions, and we describe eight independent cell lines derived from canine HSA explants. Endothelial origin was confirmed by sustained expression of surface CD105 (endoglin), CD146 (MUC18), and CD51/CD61 (alpha(v)beta(3) integrin). The cell lines showed anchorage-independent growth and were motile and invasive when cultured on a basement membrane matrix. They required endothelial growth factors for growth and survival, and they could be induced to form tubular structures resembling blood vessels when cultured under low calcium conditions. The formation of vessel-like structures was blocked by nicotine, and restored by FK506, suggesting that 'nuclear factor of activated T cells' activity prevents differentiation of these cells. In summary, these cell lines represent a unique and novel resource to improve our understanding of endothelial cell biology in general and canine HSA in particular.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064773     DOI: 10.1038/labinvest.3700080

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.

Authors:  Kipp Weiskopf; Katie L Anderson; Daisuke Ito; Peter J Schnorr; Hirotaka Tomiyasu; Aaron M Ring; Kristin Bloink; Jem Efe; Sarah Rue; David Lowery; Amira Barkal; Susan Prohaska; Kelly M McKenna; Ingrid Cornax; Timothy D O'Brien; M Gerard O'Sullivan; Irving L Weissman; Jaime F Modiano
Journal:  Cancer Immunol Res       Date:  2016-11-14       Impact factor: 11.151

2.  Identification of drug-resistant subpopulations in canine hemangiosarcoma.

Authors:  A Khammanivong; B H Gorden; A M Frantz; A J Graef; E B Dickerson
Journal:  Vet Comp Oncol       Date:  2014-08-11       Impact factor: 2.613

3.  Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.

Authors:  Jong-Hyuk Kim; Aric M Frantz; Katie L Anderson; Ashley J Graef; Milcah C Scott; Sally Robinson; Leslie C Sharkey; Timothy D O Brien; Erin B Dickerson; Jaime F Modiano
Journal:  Exp Cell Res       Date:  2014-02-25       Impact factor: 3.905

4.  Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization.

Authors:  Brandi H Gorden; Jong-Hyuk Kim; Aaron L Sarver; Aric M Frantz; Matthew Breen; Kerstin Lindblad-Toh; Timothy D O'Brien; Leslie C Sharkey; Jaime F Modiano; Erin B Dickerson
Journal:  Am J Pathol       Date:  2014-02-11       Impact factor: 4.307

5.  Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Authors:  Beth A Tamburini; Tzu L Phang; Susan P Fosmire; Milcah C Scott; Susan C Trapp; Megan M Duckett; Sally R Robinson; Jill E Slansky; Leslie C Sharkey; Gary R Cutter; John W Wojcieszyn; Donald Bellgrau; Robert M Gemmill; Lawrence E Hunter; Jaime F Modiano
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

Review 6.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

7.  Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma.

Authors:  K S Im; A J Graef; M Breen; K Lindblad-Toh; J F Modiano; J-H Kim
Journal:  Vet Comp Oncol       Date:  2015-09-03       Impact factor: 2.613

8.  Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Authors:  Melissa C Paoloni; Anita Tandle; Christina Mazcko; Engy Hanna; Stefan Kachala; Amy Leblanc; Shelley Newman; David Vail; Carolyn Henry; Douglas Thamm; Karin Sorenmo; Amin Hajitou; Renata Pasqualini; Wadih Arap; Chand Khanna; Steven K Libutti
Journal:  PLoS One       Date:  2009-03-30       Impact factor: 3.240

9.  Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes.

Authors:  Atsushi Kodama; Hiroki Sakai; Satoko Matsuura; Mami Murakami; Atsuko Murai; Takashi Mori; Kouji Maruo; Tohru Kimura; Toshiaki Masegi; Tokuma Yanai
Journal:  BMC Cancer       Date:  2009-10-14       Impact factor: 4.430

10.  Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed.

Authors:  Beth A Tamburini; Susan Trapp; Tzu Lip Phang; Jill T Schappa; Lawrence E Hunter; Jaime F Modiano
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.